Treatment patterns for relapsed and refractory Hodgkin lymphoma in a community oncology setting.
Anita J KumarChun R ChaoAngie Mae RoddayHong ChangLanfang XuAndrew M EvensSusan K ParsonsPublished in: Leukemia & lymphoma (2021)
There is little data about treatment practices for relapsed/refractory Hodgkin Lymphoma (HL) in nonacademic settings. We describe sequential treatments and outcomes among HL patients who experienced treatment failure in an integrated community-oncology setting. We performed a retrospective cohort study among patients ≥12 years diagnosed with Stage II-IV HL from 2007 to 2012 at Kaiser Permanente Southern California (KPSC). Of 463 HL patients, 75 (16.1%) experienced treatment failure. Patients with failure received between 1 and 8 salvage therapies; 28% received ≥4 lines of therapy. Fifty-nine of 75 (79%) were initially salvaged with ifosfamide-based therapy, 44 of whom underwent hematopoietic cell transplant. Ultimately, 47% of patients died, with most deaths due to HL. Survival was shorter with increasing age at diagnosis (p = 0.02) and with greater number of lines of therapy (p = 0.02). In a community oncology setting, HL patients received multiple lines of salvage. Despite extensive treatment, nearly half of patients died of HL following relapsed/refractory disease.
Keyphrases
- hodgkin lymphoma
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- prognostic factors
- mental health
- acute lymphoblastic leukemia
- palliative care
- diffuse large b cell lymphoma
- stem cells
- acute myeloid leukemia
- combination therapy
- machine learning
- patient reported outcomes
- deep learning
- smoking cessation
- cell therapy